Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash from Investing Activities (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash from Investing Activities for 16 consecutive years, with -$6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 78.37% to -$6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $61.2 million, a 81.14% decrease, with the full-year FY2024 number at $363.2 million, up 1694.6% from a year prior.
  • Cash from Investing Activities was -$6.7 million for Q3 2025 at Standard Biotools, down from $27.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $318.1 million in Q1 2024 to a low of -$138.2 million in Q2 2022.
  • A 5-year average of $16.8 million and a median of -$868000.0 in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 3213.52% in 2022, then surged 5071.66% in 2023.
  • Standard Biotools' Cash from Investing Activities stood at -$1.1 million in 2021, then skyrocketed by 3614.85% to $40.2 million in 2022, then crashed by 132.59% to -$13.1 million in 2023, then skyrocketed by 296.13% to $25.7 million in 2024, then crashed by 125.97% to -$6.7 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cash from Investing Activities are -$6.7 million (Q3 2025), $27.5 million (Q2 2025), and $14.6 million (Q1 2025).